jab-21822
Small moleculeexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Jul 26, 2021 (NCT05009329)
Timeline
Indications
Studied for
- Appendiceal Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Pancreatic Ductal · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Lung Neoplasms · Phase 2
- Mutation · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pharmacology · Phase 1
- Proto-Oncogene Proteins p21(ras) · Phase 2
- Small Cell Lung Carcinoma · Phase 3
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(F)c(F)c(F)c4F)c(Cl)cc23)CC1- Mol. weight
- 640.04 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314518 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07164170 | Phase 2 | Oct 25, 2025 | Abbisko Therapeutics Co, Ltd |
| NCT06563999 | Phase 2 | Dec 1, 2024 | Sun Yat-Sen University |
| NCT06838338 | Phase 2 | Aug 29, 2024 | Jacobio Pharmaceuticals Co., Ltd., Peking University |
| NCT06416410 | Phase 3 | Aug 7, 2024 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT06008288 | Phase 2 | Nov 30, 2023 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT06162169 | Phase 1 | Nov 25, 2023 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05920941 | Phase 1 | Jul 8, 2023 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05875493 | Phase 1 | May 12, 2023 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05276726 | Phase 1/Phase 2 (Phase 2) | Aug 17, 2022 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05288205 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2022 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05194995 | Phase 1/Phase 2 (Phase 2) | Feb 17, 2022 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05002270 | Phase 1/Phase 2 (Phase 2) | Sep 3, 2021 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05009329 | Phase 1/Phase 2 (Phase 2) | Jul 26, 2021 | Jacobio Pharmaceuticals Co., Ltd. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jacobio Pharmaceuticals Co., Ltd. | For profit | 11 | 10 | 3 | 2021 |
| Abbisko Therapeutics Co, Ltd | For profit | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1